Xipere became commercially available in March 2022. It is the first therapy for patients with macular edema that provides a targeted delivery to the retina.
The Centers for Medicare and Medicaid Services has issued a product specific J-Code for Xipere (triamcinolone acetonide) effective July 1, 2022. J-Codes are reimbursement codes used by both commercial insurers and government payers to identify therapies that are administered by a healthcare professional incident to the office visit.
“The issuance of the permanent J-Code will help facilitate access to XIPERE for Americans suffering from macular edema associated with uveitis and help streamline the reimbursement process,” Yolande Barnard, senior vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in a press release.
The FDA approved Xipere in October 2021 for treatment of macular edema associated with uveitis, a form of eye inflammation. Developed by Bausch + Lomb and Clearside Biomedical, Xipere provides a targeted delivery to the retina and choroid. Macular edema is the buildup of fluid in the macula, which causes retinal swelling and distorted vision, and if left untreated, may lead to permanent vision loss.
Related: FDA Approves Targeted Therapy for Macular Edema
Xipere became commercially available in March 2022. The new J-Code is J3299 “Injection, Triamcinolone acetonide (XIPERE).”
ICER Releases List of Drugs for Fair Access Review
June 7th 2024Included in this review will be 11 drugs that ICER assessed for cost-effectiveness in 2022. New this year is an assessment for consumer accessibility of drugs, including the burdens of prior authorization and patient cost-sharing measures.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5th 2024Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
Read More